Head of Clinical Operations

We at Syremis view our team as our key
component to success.

#48

Location:

US (East Coast)

Syremis Therapeutics is building a clinical team to advance meaningful therapies for people living with serious psychiatric conditions.

The company is looking for a Head of Clinical Operations who can lead complex clinical studies with care, structure, and clear judgment. This role is focused on psychiatry clinical trials, with strong value placed on inpatient trial experience. You will join a focused team where your work will shape study quality, patient access, and the path toward future treatment options.

About the role:

As Head of Clinical Operations, you will lead the planning and delivery of clinical trials (Phase 2 and beyond) from setup through completion. You will bring strong operational discipline and a practical approach to study challenges. You will work closely with internal teams, CROs, vendors, investigators, and study sites. You will also help build clinical operations processes that fit a growing pharmaceutical startup.

This role requires hands‑on leadership, strong ownership, and the ability to guide studies in a fast-moving setting.

• Lead the planning, setup, execution, and closeout of Phase 2 and 3 clinical studies.
• Build and lead the clinical operations team as the organization grows, including hiring, onboarding, and developing team members.
• Manage CRO selection and oversee CROs, labs, and other external vendors.
• Review and approve study plans, manuals, reports, and other trial documents.
• Guide site identification, site selection, activation, and investigator engagement.
• Monitor study progress, recruitment, budgets, timelines, risks, and issue resolution.
• Review clinical data trends and operational signals to identify risks early.
• Support mitigation plans and help teams make sound decisions.
• Conduct periodic site visits to assess study quality, enrollment, and protocol compliance.
• Monthly domestic travel may be required, with occasional international travel.

• At least 10 years of clinical operations leadership experience in biotech or pharma.
• Strong CNS trial experience, ideally in inpatient psychiatry studies.
• Led Phase 2 or 3 clinical trials and managed cross‑functional study teams.
• Strong knowledge of GCP/ICH guidelines and quality expectations.
• Great interpersonal skills
• A bachelor’s degree, preferably in the life sciences, nursing, or a related field

Reid Huber joined Third Rock in 2018 as a Partner, bringing more than 25 years of leadership and experience to the role. He focuses on the formation, development, and strategy of Third Rock’s portfolio companies. Reid served as Interim CEO of MOMA Therapeutics until the appointment of Dr. Asit Parikh in Spring of 2021, of Rapport Therapeutics until the appointment of Abe Ceesay in the Spring of 2023, and of Merida Biosciences until the appointment of Adam Townsend in the Spring of 2025.

Reid joined TRV from Incyte, where he was a member of the founding scientific team and most recently served as executive vice president and chief scientific officer. At Incyte, he held roles of increasing responsibility across multiple therapeutic areas in both drug discovery and clinical development. In 2011, he assumed responsibility for the company’s research and early development activities. Before joining Incyte, Reid held scientific research positions at DuPont Pharmaceuticals and Bristol-Myers Squibb from 1998 to 2002.

He received his Ph.D. in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes of Health.

Reid is a board director at Rapport Therapeutics, Merida Biosciences, Terremoto, Synnovation Therapeutics, MOMA Therapeutics, Asher Biotherapeutics, and a board observer at insitro.